International journal of clinical oncology
-
Int. J. Clin. Oncol. · Aug 2018
ReviewRecent advances in medical therapy for metastatic urothelial cancer.
Cytotoxic chemotherapy has been the mainstay of medical therapy for metastatic urothelial cancer. Currently, the gemcitabine/cisplatin regimen is widely used worldwide as the standard first-line medical treatment. ⋯ The paradigm of medical treatment for patients with metastatic UC is dramatically changing through the introduction of this and other immune-checkpoint inhibitors. In this article, we provide a brief overview of these immune-checkpoint inhibitors and a comprehensive summary of the use of cytotoxic chemotherapy for metastatic urothelial cancer, including ongoing clinical trials.
-
Int. J. Clin. Oncol. · Aug 2018
Hibernation of masses suspected to be remnant tumors after surgical resection of retroperitoneal liposarcoma is related to improved overall survival.
Although complete surgical resection is considered the best treatment for retroperitoneal liposarcoma, it is related to a high local recurrence rate. This study analyzed patterns of recurrence of retroperitoneal liposarcoma. ⋯ Hibernation of a recurrence-suspected mass was related to improvement of overall survival in patients with a mass detected within 6 months. This specific patient group should be monitored with care to see if the size of the mass increases. When a mass seemed to be hibernating, a favorable prognosis could be expected.